This year, the European Medicines Agency's activities will concentrate on
the implementation of the pharmacovigilance legislation and preparations for
the new legislation on falsified medicines, according to the work
programme 2012, published last week.
The document, adopted by the Agency’s Management Board at its meeting on 15 December 2011, forecasts a stable number of
applications for marketing authorisation for human and veterinary medicines in
2012.
It states that the Agency will continue to review its activities and
processes so that it can identify areas where efficiency gains, re-allocation
of resources and reprioritisation of activities may be possible. This should
put the Agency in a position to manage its increased responsibilities with
existing resources.
In line with the road
map implementation plan, the Agency will strengthen
the quality and the regulatory and scientific consistency of its assessment
process and its outputs where needed.
The Agency will also increase its levels of transparency, advance its
initiatives in the area of communication and interaction with stakeholders,
deliver on public-health needs, support the availability of veterinary
medicines and support the review of veterinary legislation.
The Agency publishes a work programme every year in English. It will
publish the introduction of the 2012 work programme translated into all
official European Union languages later in the year.